Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.41 |
| ▸ | RBP4 | P02753 | 5/20 | 0.39 |
| ▸ | APLNR | P35414 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3695868 | 0.91 | PROKR1 (0.44) | PROKR1ROCK2RBP4APLNRMAPT | |
| SCHEMBL3683970 | 0.90 | ROCK2 (0.51) | PROKR1ROCK2RBP4MAPTRAB9A | |
| SCHEMBL3696196 | 0.88 | ROCK2 (0.43) | PROKR1ROCK2RBP4RAB9A | |
| SCHEMBL3687393 | 0.87 | ROCK2 (0.43) | PROKR1ROCK2RBP4 | |
| SCHEMBL3708965 | 0.87 | RBP4 (0.46) | ROCK2RBP4 | |
| SCHEMBL3695694 | 0.86 | ROCK2 (0.38) | PROKR1ROCK2RBP4MAPTRAB9A | |
| SCHEMBL3685888 | 0.85 | MAPT (0.39) | PROKR1RBP4APLNRMAPTRAB9A | |
| SCHEMBL3704741 | 0.84 | ROCK2 (0.40) | PROKR1ROCK2RBP4 | |
| SCHEMBL3689619 | 0.84 | RBP4 (0.45) | PROKR1ROCK2RBP4APLNRMAPT | |
| SCHEMBL3690446 | 0.83 | PROKR1 (0.36) | PROKR1ROCK2RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | GLAXOSMITHKLINE LLC | 2012-05-17 | — | — | US | disclosed |
| CN-101842098-A | Nitrogen-containing bicyclic chemical entities for the treatment of viral infections | GENELABS TECH INC | 2010-09-22 | — | — | CN | disclosed |
| EP-2187883-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | GLAXOSMITHKLINE LLC | 2009-07-09 | — | — | US | disclosed |
| WO-2009023179-A2 | NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121540-A1 | Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections | OAT, HAVCR2, CPS1 | PROKR1 4829/4885ROCK2 4811/4885RBP4 1868/4885 |
| US-20090176778-A1 | Certain nitrogen containing bicyclic chemical entities for treating viral infections | OAT, HAVCR2, CPS1 | PROKR1 4829/4885ROCK2 4811/4885RBP4 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.